Highlights
- A systematic review of 1,371 patients found no significant difference in 5-year mortality or overall survival between total thyroidectomy and lobectomy for sporadic medullary thyroid cancer (sMTC).
- Biochemical cure rates and structural recurrence at 5 years were statistically similar between surgical groups.
- Total thyroidectomy was associated with a significantly higher risk of postoperative complications compared to lobectomy.
- Findings suggest that for selected patients with small (<2 cm), unilateral, node-negative sMTC, lobectomy may be an oncologically safe alternative.
Background
Medullary thyroid cancer (MTC) represents approximately 1% to 2% of all thyroid malignancies. Traditionally, the surgical standard for all MTC cases—whether hereditary or sporadic—has been total thyroidectomy (TT) accompanied by central neck dissection (CND). This aggressive approach was predicated on the potential for multicentricity, particularly in cases associated with RET proto-oncogene mutations, and the historically poor response of MTC to adjuvant therapies such as radioiodine or chemotherapy.
However, sporadic medullary thyroid cancer (sMTC) is typically unilateral and unifocal, unlike the multifocal nature of hereditary forms. As diagnostic techniques and risk stratification have improved, the necessity of total thyroidectomy for localized, unilateral sporadic disease has come under scrutiny. Clinicians must balance the goal of oncologic clearance with the morbidity of total thyroidectomy, including permanent hypocalcemia and recurrent laryngeal nerve injury. This review synthesizes the latest evidence comparing the efficacy and safety of total thyroidectomy versus lobectomy (TL) in the management of sMTC.
Key Content
Study Characteristics and Patient Demographics
A comprehensive meta-analysis of nine retrospective studies comprising 1,371 patients was conducted. Of these, 531 patients (38.7%) underwent lobectomy, while 840 (61.3%) underwent total thyroidectomy. The median age of participants ranged from 45.0 to 58.2 years, with a female predominance (74.3%).
The cohort largely represented early-stage disease: 82.1% of tumors lacked extrathyroidal extension, 70.8% were smaller than 2 cm, and 57.4% were node-negative at the time of surgery. Multifocal disease was rare, occurring in only 9.1% of patients. Notably, central neck dissection was performed in the majority of cases (90.4%).
Survival and Mortality Outcomes
The primary concern in de-escalating surgical extent is the impact on survival. The meta-analysis revealed that mortality did not differ significantly between patients undergoing total thyroidectomy and those undergoing lobectomy at the 5-year mark (Relative Risk [RR], 0.30; 95% CI, 0.07-1.35) or in long-term follow-up beyond 5 years (RR, 1.00; 95% CI, 0.40-2.47). Similarly, overall survival at 5 years remained comparable between both surgical groups (RR, 1.02; 95% CI, 0.94-1.11).
Recurrence and Biochemical Cure
Oncologic control was further evaluated through structural recurrence and biochemical cure rates:
- Structural Recurrence: At 5 years, total thyroidectomy was not associated with lower recurrence rates compared to lobectomy (OR, 0.45; 95% CI, 0.14-1.49). However, beyond 5 years, the data showed a statistical association (OR, 7.26; 95% CI, 1.07-49.21), though this should be interpreted with caution due to the retrospective nature and potential selection bias of the included studies.
- Biochemical Cure: Achieving undetectable postoperative calcitonin levels is a hallmark of successful MTC surgery. No significant differences were observed in biochemical cure rates at 5 years (OR, 0.86; 95% CI, 0.47-1.56) or beyond (OR, 0.87; 95% CI, 0.26-2.89).
- Distant Metastasis: The development of distant metastasis at 5 years did not differ between the two surgical approaches (OR, 1.64; 95% CI, 0.09-31.52).
Safety and Postoperative Complications
A critical secondary outcome was the rate of surgical complications. The synthesis indicated that total thyroidectomy was associated with a higher incidence of postoperative complications, primarily transient or permanent hypoparathyroidism and vocal cord paralysis. This finding underscores the potential morbidity benefits of a more conservative lobectomy approach in appropriately selected patients.
Expert Commentary
The findings of this meta-analysis challenge the conventional “one-size-fits-all” surgical paradigm for sMTC. While hereditary MTC mandates total thyroidectomy due to nearly universal multicentricity, the clinical behavior of sporadic disease appears to mirror that of differentiated thyroid cancers where lobectomy has already gained acceptance for low-risk tumors.
The biological rationale for lobectomy in sMTC lies in the low rate of multifocality (under 10%) observed in this population. If a tumor is unilateral and there is no evidence of RET germline mutation, the contralateral lobe effectively harbors no increased risk compared to the general population. However, several caveats remain:
- Selection Bias: The included studies were retrospective, meaning patients receiving lobectomy likely had smaller, more favorable tumors. Although sensitivity analyses suggested consistency, the risk of bias was rated high or moderate in 8 out of 9 studies.
- Preoperative Evaluation: Accurate preoperative staging with high-resolution ultrasound and calcitonin levels is essential. A baseline calcitonin level significantly above the normal range may suggest systemic or nodal disease, making lobectomy less appropriate.
- The Role of CND: Since MTC frequently metastasizes to lymph nodes even when the primary tumor is small, the necessity of central neck dissection regardless of the extent of thyroidectomy remains a point of debate that requires further prospective study.
Conclusion
Current evidence suggests that for selected patients with sporadic medullary thyroid cancer—specifically those with small, unilateral tumors and no evidence of extrathyroidal extension or nodal involvement—thyroid lobectomy may be an oncologically safe alternative to total thyroidectomy. Lobectomy is associated with similar 5-year survival and recurrence rates while significantly reducing the risk of surgical complications. Until large-scale prospective trials are available, surgical decisions should be individualized, incorporating multidisciplinary input and patient preference regarding the trade-off between maximal surgical clearance and quality-of-life considerations.
References
- Lincango EP, Vilatuna-Andrango L, Arce-Camposano A, et al. Total Thyroidectomy vs Lobectomy for Sporadic Medullary Thyroid Cancer: A Systematic Review and Meta-Analysis. JAMA Otolaryngol Head Neck Surg. 2026 Feb 26. doi: 10.1001/jamaoto.2025.5599. PMID: 41746657.
- Wells SA Jr, Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015;25(6):567-610. PMID: 25810047.
